Part of LG Chem Ltd.
Clinical Trials
86
46 active
Approvals
3
Total approvals
Agencies
1
Regulatory bodies
Founded
2001
Active, not recruiting
46
53.5%
Completed
24
27.9%
No Longer Available
1
1.2%
Recruiting
6
7.0%
Terminated
6
7.0%
Withdrawn
1
1.2%
- AVEO Oncology and HiberCell announced an exclusive development and option agreement for HC-5404, a first-in-human PERK inhibitor, to be combined with AVEO's approved VEGFR inhibitor FOTIVDA for renal cell carcinoma treatment. - Pre-clinical studies demonstrate HC-5404's enhanced anti-tumor efficacy when combined with anti-angiogenic agents in multiple solid tumor models including gastric cancer and RCC. - AVEO will conduct initial clinical development and has the option to obtain exclusive worldwide licensing rights during Phase 2 trials, with HiberCell eligible for milestone payments and royalties. - The collaboration leverages HC-5404's novel mechanism targeting the Unfolded Protein Response pathway, which cancer cells use to survive harsh tumor microenvironments.
- Over 90 pharmaceutical and biotech companies are actively developing more than 95 pipeline drugs for hepatocellular carcinoma (HCC). - Key companies like Can-Fite BioPharma are advancing HCC drug candidates, with some therapies in Phase III clinical trials. - Emerging therapies such as Namodenoson, SRF388, and Porustobart are expected to significantly impact the HCC market in the coming years. - The pipeline includes diverse routes of administration and molecule types, offering varied treatment options for HCC.
